Cancer remains one of the leading causes of mortality worldwide, accounting for nearly 10 million deaths annually. Despite decades of progress in oncology, many treatments continue to face a fundamental challenge: how to effectively eliminate tumour cells while minimising damage to healthy tissues. Conventional chemotherapy, although effective in certain settings, often leads to significant systemic toxicity and debilitating side effects that limit patient tolerance and treatment outcomes.

To address this challenge, antibody–drug conjugates (ADCs) have emerged as one of the most promising therapeutic modalities in oncology. ADCs combine the targeting specificity of monoclonal antibodies with the potent cell-killing ability of cytotoxic payloads, connected via specialised linker technologies. This design enables the selective delivery of highly potent drugs directly to tumour cells, improving therapeutic precision and potentially reducing off-target toxicity.

As a result, ADCs have become a major strategic focus across the global biopharmaceutical industry, with the majority of the world’s top pharmaceutical companies investing heavily in ADC pipelines, next-generation payloads, and advanced bioconjugation technologies.

The United Kingdom plays a critical role in this rapidly evolving ecosystem. As a global life sciences innovation hub, the UK hosts major pharmaceutical companies alongside a vibrant network of emerging biotech innovators developing novel ADC platforms, targets, and enabling technologies. From Cambridge and Oxford to London and Stevenage, these organisations are advancing the next generation of targeted oncology therapies addressing both solid tumours and haematological malignancies.

The following overview highlights key large pharmaceutical companies with ADC activities and a presence in the UK, alongside emerging biotech companies and technology innovators contributing to the growing ADC landscape.